INSIGHT BANK · 28 LIVING CARDS
Follow a question.
See what changes.
Evidence, technologies, people and the next test—connected, but not confused.
Commercializationv4 · 09.23
How far will broader coverage translate into new screening and diagnostic follow-up?
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
- ✓Policy announcementRecorded
- ◷January 2027 implementationScheduled
- ?Testing and paymentUnverified
- ?Follow-up colonoscopyUnverified
Additional source checkedAdded planned EviCore implementation; prior clinical-performance assessment is unchanged.
NEXT CHECKTrack implementation, tests and payments, participation by previously unscreened people, and completed follow-up colonoscopies separately.
R&D Allocationv3 · 09.07
Whose research opportunities follow compute investment?
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
- ✓Open callRecorded
- ◷AwardsScheduled
- ◷StartScheduled
- ?OutcomesUnverified
Additional source checkedUpdated the related analysis after further source checks. This is not a newly announced trial or experiment.
NEXT CHECKCheck eligibility, collaborators, compute allocations, publication and IP terms. Deadline: December 1 at noon ET; decisions scheduled for March 1, 2027.
Frontier Sciencev3 · 09.07
What supports memory when synapses change?
Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory.
- ✓Retention in hibernationRecorded
- ✓Sleep and ongoing changeRecorded
- ?Tolerated changesUnverified
- ?Readout testsUnverified
Additional source checkedUpdated the related analysis after further source checks. This is not a newly announced trial or experiment.
NEXT CHECKMatched perturbations with different targets, fixed versus adaptive readout, and retention with or without relearning.
Commercializationv3 · 09.07
Where might linked diagnostic and therapy approvals stall in practice?
Concurrent approvals. Uptake and payment for the new use remain open.
- ✓Drug & CDxRecorded
- ?UptakeUnverified
- ?PaymentUnverified
- ?Real-world useUnverified
Analysis addedAdded a short reading on treatment-switch timing, ongoing monitoring and the practical and payment conditions for adoption.
NEXT CHECKConfirmatory trials, payer policies for the new use and clinical uptake.
Frontier Sciencev3 · 09.07
How should hypothesis-generating AI be verified and steered?
Preprint located. Human steering becomes a testable focus.
- ✓AI explorationRecorded
- ✓Expert steeringRecorded
- ✓Within-case checksRecorded
- ?Independent replicationUnverified
Analysis addedAdded a short reading on researcher guidance, efficiency including expert time and replication by other teams.
NEXT CHECKEvaluation conditions, failure cases and replication on other data by independent teams.
Frontier Sciencev2 · 09.07
Can an AI-surfaced immune signal inform treatment research?
Validation in additional data and tissue reported. Treatment benefit is unproven.
- ✓AI hypothesisRecorded
- ✓Additional datasetRecorded
- ✓Tumor tissueRecorded
- ?Treatment effectUnverified
Analysis addedAdded a short reading on distinguishing patient groups by immune characteristics and testing the link to treatment response.
NEXT CHECKPeer review, replication by another team and prospective tests of the treatment hypothesis.
R&D Allocationv2 · 09.07
How far can measurement resolve a question about memory?
CLEM used in the same study. Observation is not intervention.
- ✓Method usedRecorded
- ✓Structure linkedRecorded
- ?TransferUnverified
- ?AdoptionUnverified
Analysis addedAdded a short reading on what CLEM measures, reuse of the method, and its combination with activity recording and intervention.
NEXT CHECKMethod reuse, implementations in other studies and the skills and equipment required.
Commercializationv3 · 10.13
After a candidate is found, how far is it validated, and who retains rights to the results?
The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs.
- ✓Lab and testing support announcedRecorded
- ?Access terms and rightsUnverified
- ?Use and continuing demandUnverified
Additional source checkedAdded Ginkgo’s in-kind NSF X-Labs support, separated programme scale from company compensation, and identified usage and rights terms for follow-up.
NEXT CHECKUse of contributed capacity, experimental outcomes, access and data-reuse terms, and demand after the support ends.
R&D Allocationv1 · 09.23
Who checks clinical AI decisions, and how is that supervision itself evaluated?
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
- ✓Program and awardsRecorded
- ?DevelopmentUnverified
- ?Clinical evaluationUnverified
- ?AuthorizationUnverified
New question openedPublished the analysis and recorded the next checks.
NEXT CHECKMissed errors, false alarms, appropriate clinical handoffs and evaluation in routine care.
Frontier Sciencev1 · 09.23
Does transplanted neural tissue help surviving circuits, take over missing functions, or both?
A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons.
- ✓Survival and connectionsRecorded
- ✓Behavioral tasksRecorded
- ?Necessity of activityUnverified
- ?Application after injuryUnverified
New question openedPublished the analysis and recorded the next checks.
NEXT CHECKManipulate graft activity during specific tasks to distinguish modulation of host circuits from information processing.
Frontier Sciencev1 · 09.23
Which differences in treatment response do measured differences between patients represent?
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
- ✓Historical dataRecorded
- ✓Prospective trialRecorded
- ?Selection utilityUnverified
- ?ReplicationUnverified
New question openedPublished the analysis and recorded the next checks.
NEXT CHECKDrug comparisons at the same treatment stage, and separate validation of early changes to inform subsequent decisions.
Frontier Sciencev1 · 09.23
What do new hippocampal neurons contribute to preserving and updating memory?
A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts.
- ✓Human postmortem associationRecorded
- ✓Mouse behavioral taskRecorded
- ?Retention versus updatingUnverified
- ?Causality in humansUnverified
New question openedAdded a short reading separating memory retention from updating.
NEXT CHECKRelate cell stage and circuit integration to memory retention, context discrimination and relearning.
Commercializationv1 · 09.29
How can molecular evidence of residual cancer guide postoperative treatment?
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKTrack the authorized population and treatment conditions.
R&D Allocationv1 · 09.29
Can cells retain their function through room-temperature storage and transport?
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKStorage duration by cell type, recovered function and independent ATCC testing.
Frontier Sciencev1 · 09.29
How can receptor-directed autoimmunity be identified among patients with similar symptoms?
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKPatient selection, CSF-inclusive assessment, and ART5803 safety and clinical outcomes.
Commercializationv1 · 09.29
Which patients and product proposition could make a discontinued program viable?
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKPatient selection, functional endpoints, long-term evidence and licensing terms.
Commercializationv2 · 10.13
How are costs, rights and returns shared when another company’s technology enables a treatment?
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
- ✓PFS result announcedRecorded
- ?Prespecified OS assessmentUnverified
- ?Detailed resultsUnverified
Additional source checkedAdded the BNT113 PFS result and continuation of the prespecified OS assessment.
NEXT CHECKThe planned OS analysis, detailed PFS results, and explanations of the population and safety findings.
R&D Allocationv1 · 10.09
Who pays for the work of making AI-enabled trials viable, and what do they buy?
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedExamine continuing operations and payment for AI-enabled trials through the SURPASS solicitation.
NEXT CHECKSelected teams, trial execution, payment by later sponsors and terms for model and patient-data use.
Frontier Sciencev1 · 10.09
How can shared learning remain useful without confusing different contexts?
Mouse tasks with different actions and a shared reward delay showed shared cortical activity and task-dependent cerebellar separation that preserved temporal structure. A computational model combined faster learning with reduced interference.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedUse cerebellar population activity to distinguish shared learning from interference across tasks.
NEXT CHECKInterference when representational separation is manipulated, transfer to novel tasks and which temporal relationships remain stable.
Commercializationv1 · 10.13
What benefit comes from detecting a resistance mutation and switching treatment before radiographic progression?
European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression.
- ✓PFS benefit in selected patientsRecorded
- ?Compare early and progression-time switchingUnverified
- ?Long-term benefit and uptakeUnverified
New question openedLinked European CDx certification, SERENA-6, SERENA-4 and FDA confirmation requirements through the question of treatment timing.
NEXT CHECKComparison of early and post-progression use of the same drug, longer-term survival and uptake in the indicated population.
R&D Allocationv1 · 10.13
How reliably can research AI lead to antibody candidates that meet the requirements of a particular application?
A common-condition study of 511 sequences from 29 organizations found different performance in improvement and ranking tasks. Cradle’s high-affinity candidate passed the aggregate threshold but retained concerns in individual developability assays.
- ✓Blinded comparison under common conditionsRecorded
- ?Compare application-specific requirementsUnverified
- ?Reproducibility across targetsUnverified
New question openedDistinguished antibody design, selection and development decisions, and recorded aggregate scoring alongside individual concerns.
NEXT CHECKReproducibility across targets, yield of candidates meeting required conditions, synthesis and assay counts, and cost and time to a development decision.
Frontier Sciencev1 · 10.13
As neural representations change, what must remain and what must a reader update to keep using the same information?
Flexible electrodes tracked the same mouse neurons over months. Aligning activity across recording days improved decoding of temporal information in a repeated movie. The analysis also used responses from the new day.
- ✓Longitudinal tracking of the same cellsRecorded
- ✓Alignment across recording daysRecorded
- ?Maintenance mechanisms in the brainUnverified
New question openedDistinguished stable long-term recording from changing representations, using new-day alignment to consider adaptive readout.
NEXT CHECKDistinguish reader adaptation from stable information components, and examine the learning that maintains their correspondence or its breakdown.
Commercializationv1 · 10.19
How much can easier administration contribute to treatment initiation and drug sales in thyroid eye disease?
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
- ✓New US indication approvedRecorded
- ?Track patient uptakeUnverified
- ?Compare indication-specific salesUnverified
New question openedRecord the new indication, the two trial outcomes and the administration route, and begin tracking uptake and indication-specific sales.
NEXT CHECKFollow disclosed new treatment starts, switches from other therapies and indication-specific sales in thyroid eye disease, separately from total Enspryng revenue.
R&D Allocationv1 · 10.19
Can comparing skin and lung fibrosis provide evidence for deciding which diseases to pursue with a drug?
3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
- ✓Research plan describedRecorded
- ?Test shared and distinct responsesUnverified
- ?Inform indication selectionUnverified
New question openedRecord a research plan to use shared fibrotic processes and organ differences in indication selection.
NEXT CHECKCandidates with shared responses across skin and lung models, conditions that separate responses, reproducibility across donor samples and subsequent development decisions.
Frontier Sciencev1 · 10.19
Which conditions separate placental and fetal outcomes after the same maternal immune challenge?
Within 24 hours of immune stimulation in mice, developmental abnormalities were reported in roughly 30% of fetuses, limited to a subset of males. Affected fetuses also showed placental inflammatory changes, structural disruption and immune-cell and cytokine accumulation in amniotic fluid.
- ✓Acute heterogeneity observedRecorded
- ?Test the role of local conditionsUnverified
- ?Connect to longer-term developmentUnverified
New question openedSeparate the ASD research context, current acute findings and earlier placental IL-6 intervention, and add the question of local environment.
NEXT CHECKResearch separating placental inflammatory regulation, structural maintenance and developmental timing, and testing whether changing local conditions alters fetal outcomes.
Commercializationv1 · 10.24
At what quality, turnaround time and cost can patient-specific medicines be supplied repeatedly?
The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
- ✓Phase 3 results reportedRecorded
- ?Assess regulation and supplyUnverified
- ?Commercial scale and costsUnverified
New question openedRecord phase 3 results and supply roles, and track patient-level manufacturing and delivery conditions.
NEXT CHECKRegulatory decisions, specimen-to-delivery time, manufacturing success, per-patient costs and indication-specific outcomes.
R&D Allocationv1 · 10.24
Can a model learn intervention–response relationships and predict responses in unmeasured cellular conditions?
The Virtual Biology Initiative expands joint experimental-data infrastructure. Separately, Arc’s 2026 challenge tests response prediction without providing perturbation outcomes in the target cells.
- ✓Shared infrastructure expandedRecorded
- ?Add perturbation dataUnverified
- ?Evaluate unseen conditionsUnverified
New question openedRecord investment in shared experimental data separately from evaluation in unseen conditions.
NEXT CHECKAdded cells and interventions, independently evaluated predictive performance, and data-release and reuse conditions.
Frontier Sciencev1 · 10.24
Which changes in ACE abundance, catalytic activity or localization matter for neural function and disease?
The study reports lower ACE protein abundance associated with early-stage psychosis and treatment resistance, but no significant group difference in enzyme activity per unit serum volume.
- ✓Association observed in patientsRecorded
- ?Disentangle functionsUnverified
- ?Causal links to diseaseUnverified
New question openedSeparate early-psychosis observations, prior depression research and editorial experimental proposals.
NEXT CHECKSeparate abundance, activity and localization in patient-derived cells and mice; distinguish circuit and behavioral measures from blood-pressure and locomotor effects.